Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model

Vaccine

Volumn 28, Issue 37, 2010, Pages 6028-6035

  Bui, Melanie R ^a   Hodson, Victoria ^b   King, Tom ^b   Leopold, Derek ^a   Dai, Shaodong ^a   Fiolkoski, Valerie ^b   Oakes, Sarah ^b   Duke, Richard ^b   Apelian, David ^b   Franzusoff, Alex ^b   DeGregori, James ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b GlobeImmune Inc   (United States)

Author keywords

BCR ABL; Immunotherapy; T315I

Indexed keywords

BCR ABL PROTEIN; DASATINIB; GAMMA INTERFERON; IMATINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NILOTINIB; VIRUS VACCINE; CANCER VACCINE; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; GENETIC RECOMBINATION; GENETIC REGULATION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMICAL STRUCTURE; DISEASE FREE SURVIVAL; GENE; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; SACCHAROMYCES CEREVISIAE;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; DISEASE-FREE SURVIVAL; FUSION PROTEINS, BCR-ABL; GENES, MHC CLASS I; IMMUNOTHERAPY; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; SACCHAROMYCES CEREVISIAE; VACCINES, SYNTHETIC;

EID: 77955511509     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.085     Document Type: Article

References (43)

1. Nowell P., Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1488-1501.
2. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243(June (5405)):290-293.
3. Kurzrock R., Gutterman J.U., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988, 319(October (15)):990-998.
4. Maurer J., Janssen J.W., Thiel E., van Denderen J., Ludwig W.D., Aydemir U., et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991, 337(May (8749)):1055-1058.
5. Westbrook C.A., Hooberman A.L., Spino C., Dodge R.K., Larson R.A., Davey F., et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992, 80(December (12)):2983-2990.
6. Gleissner B., Gokbuget N., Bartram C.R., Janssen B., Rieder H., Janssen J.W., et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002, 99(March (5)):1536-1543.
7. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 1999, 340(April (17)):1330-1340.
8. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344(April (14)):1038-1042.
9. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(March (11)):994-1004.
10. Quintas-Cardama A., Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?. Curr Oncol Rep 2009, 11(September (5)):337-345.
11. Quintas-Cardama A., Kantarjian H., Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009, 6(9 (Sep)):535-543.
12. Shah N.P., Sawyers C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003, 22(October (47)):7389-7395.
13. Williams R.T., Sherr C.J. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias. Cold Spring Harb Symp Quant Biol 2008, 73:461-467.
14. Nicolini F.E., Corm S., Le Q.H., Sorel N., Hayette S., Bories D., et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006, 20(June (6)):1061-1066.
15. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12(December (24)):7374-7379.
16. Jabbour E., Kantarjian H., Jones D., Talpaz M., Bekele N., O'Brien S., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20(October (10)):1767-1773.
17. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354(June (24)):2531-2541.
18. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354(June (24)):2542-2551.
19. Azam M., Nardi V., Shakespeare W.C., Metcalf C.A., Bohacek R.S., Wang Y., et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006, 103(June (24)):9244-9249.
20. de Lavallade H., Khorashad J.S., Davis H.P., Milojkovic D., Kaeda J.S., Goldman J.M., et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007, 110(October (7)):2779-2780.
21. Quintas-Cardama A., Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008, 14(July (14)):4392-4399.
22. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108(July (1)):28-37.
23. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(August (2)):117-125.
24. Roche-Lestienne C., Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol 2003, 40(April (2 Suppl. 2)):80-82.
25. Lu Y., Bellgrau D., Dwyer-Nield L.D., Malkinson A.M., Duke R.C., Rodell T.C., et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004, 64(August (15)):5084-5088.
26. Munson Coupling Innate Adaptive Immunity with Yeast-Based Cancer Immunotherapy 2008.
27. Bui H.H., Sidney J., Peters B., Sathiamurthy M., Sinichi A., Purton K.A., et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57(June (5)):304-314.
28. Udaka K., Wiesmuller K.H., Kienle S., Jung G., Tamamura H., Yamagishi H., et al. An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries. Immunogenetics 2000, 51(August (10)):816-828.
29. Peters B., Tong W., Sidney J., Sette A., Weng Z. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules. Bioinformatics 2003, 19(September (14)):1765-1772.
30. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994, 152(January (1)):163-175.
31. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50(November (3-4)):213-219.
32. Vladimir Brusic GR, Leonard C. Harrison Prediction of MHC Binding Peptides Using Artificial Neural Networks. Complexity International 1995, 1995; 02.
33. Fremont D.H., Matsumura M., Stura E.A., Peterson P.A., Wilson I.A. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992, 257(August (5072)):919-927.
34. Fremont D.H., Stura E.A., Matsumura M., Peterson P.A., Wilson I.A. Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Proc Natl Acad Sci USA 1995, 92(March (7)):2479-2483.
35. Kaplan W., Littlejohn T.G. Swiss-PDB viewer (deep view). Brief Bioinform 2001, 2(May (2)):195-197.
36. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998, 54(September (Pt 5)):905-921.
37. Jones T.A.Z.J.-Y., Cowan S.W. mproved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr Sect A 1991, 2(42):110-119.
38. Bilousova G., Marusyk A., Porter C.C., Cardiff R.D., DeGregori J. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol 2005, 3(December (12)):e401.
39. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001, 7(May (5)):625-629.
40. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65(June (11)):4500-4505.
41. Van Etten R.A. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene 2002, 21(December (56)):8643-8651.
42. Williams R.T., Roussel M.F., Sherr C.J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006, 103(April (17)):6688-6693.
43. Mumprecht S., Schurch C., Schwaller J., Solenthaler M., Ochsenbein A.F. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009, 114(August (8)):1528-1536.